The indigenous CAR‑T therapy has shown maximum efficacy against B‑ALL and which other blood cancer?

The correct option is Non‑Hodgkin Lymphoma.

Explanation:
CAR-T (Chimeric Antigen Receptor T-cell) therapy is an innovative form of immunotherapy that genetically modifies a patient's own T cells to target and destroy cancer cells.

India's first indigenous CAR-T cell therapy, known as NexCAR19 (Actalycabtagene autoleucel), was developed by ImmunoACT along with IIT Bombay and Tata Memorial Hospital. It is engineered to target the CD19 protein, which is expressed on the surface of B-cell lineage malignancies.

NexCAR19 has demonstrated maximum efficacy in treating two primary types of blood cancers:
1. B-cell Acute Lymphoblastic Leukaemia (B-ALL)
2. Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Therefore, alongside B-ALL, the therapy has shown maximum efficacy against Non‑Hodgkin Lymphoma.